Cargando…
Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
Osteoporosis is a chronical, systemic skeletal disorder characterized by an increase in bone resorption, which leads to reduced bone density. The reduction in bone mineral density and therefore low bone mass results in an increased risk of fractures. Osteoporosis is caused by an imbalance in the nor...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836178/ https://www.ncbi.nlm.nih.gov/pubmed/35163315 http://dx.doi.org/10.3390/ijms23031393 |
_version_ | 1784649613352894464 |
---|---|
author | Tonk, Christian Horst Shoushrah, Sarah Hani Babczyk, Patrick El Khaldi-Hansen, Basma Schulze, Margit Herten, Monika Tobiasch, Edda |
author_facet | Tonk, Christian Horst Shoushrah, Sarah Hani Babczyk, Patrick El Khaldi-Hansen, Basma Schulze, Margit Herten, Monika Tobiasch, Edda |
author_sort | Tonk, Christian Horst |
collection | PubMed |
description | Osteoporosis is a chronical, systemic skeletal disorder characterized by an increase in bone resorption, which leads to reduced bone density. The reduction in bone mineral density and therefore low bone mass results in an increased risk of fractures. Osteoporosis is caused by an imbalance in the normally strictly regulated bone homeostasis. This imbalance is caused by overactive bone-resorbing osteoclasts, while bone-synthesizing osteoblasts do not compensate for this. In this review, the mechanism is presented, underlined by in vitro and animal models to investigate this imbalance as well as the current status of clinical trials. Furthermore, new therapeutic strategies for osteoporosis are presented, such as anabolic treatments and catabolic treatments and treatments using biomaterials and biomolecules. Another focus is on new combination therapies with multiple drugs which are currently considered more beneficial for the treatment of osteoporosis than monotherapies. Taken together, this review starts with an overview and ends with the newest approaches for osteoporosis therapies and a future perspective not presented so far. |
format | Online Article Text |
id | pubmed-8836178 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88361782022-02-12 Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad? Tonk, Christian Horst Shoushrah, Sarah Hani Babczyk, Patrick El Khaldi-Hansen, Basma Schulze, Margit Herten, Monika Tobiasch, Edda Int J Mol Sci Review Osteoporosis is a chronical, systemic skeletal disorder characterized by an increase in bone resorption, which leads to reduced bone density. The reduction in bone mineral density and therefore low bone mass results in an increased risk of fractures. Osteoporosis is caused by an imbalance in the normally strictly regulated bone homeostasis. This imbalance is caused by overactive bone-resorbing osteoclasts, while bone-synthesizing osteoblasts do not compensate for this. In this review, the mechanism is presented, underlined by in vitro and animal models to investigate this imbalance as well as the current status of clinical trials. Furthermore, new therapeutic strategies for osteoporosis are presented, such as anabolic treatments and catabolic treatments and treatments using biomaterials and biomolecules. Another focus is on new combination therapies with multiple drugs which are currently considered more beneficial for the treatment of osteoporosis than monotherapies. Taken together, this review starts with an overview and ends with the newest approaches for osteoporosis therapies and a future perspective not presented so far. MDPI 2022-01-26 /pmc/articles/PMC8836178/ /pubmed/35163315 http://dx.doi.org/10.3390/ijms23031393 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tonk, Christian Horst Shoushrah, Sarah Hani Babczyk, Patrick El Khaldi-Hansen, Basma Schulze, Margit Herten, Monika Tobiasch, Edda Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad? |
title | Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad? |
title_full | Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad? |
title_fullStr | Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad? |
title_full_unstemmed | Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad? |
title_short | Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad? |
title_sort | therapeutic treatments for osteoporosis—which combination of pills is the best among the bad? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836178/ https://www.ncbi.nlm.nih.gov/pubmed/35163315 http://dx.doi.org/10.3390/ijms23031393 |
work_keys_str_mv | AT tonkchristianhorst therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad AT shoushrahsarahhani therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad AT babczykpatrick therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad AT elkhaldihansenbasma therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad AT schulzemargit therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad AT hertenmonika therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad AT tobiaschedda therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad |